The malignant phenotype in breast cancer is driven by aberrant signal transduction pathways. Mixed-lineage kinase-3 (MLK3) is a mammalian mitogen-activated protein kinase kinase kinase (MAP3K) that activates multiple MAPK pathways. Depending on the cellular context, MLK3 has been implicated in apoptosis, proliferation, migration and differentiation. Here we investigated the effect of MLK3 and its signaling to MAPKs in the acquisition of malignancy in breast cancer. We show that MLK3 is highly expressed in breast cancer cells. We provide evidence that MLK3's catalytic activity and signaling to c-jun N-terminal kinase (JNK) is required for migration of highly invasive breast cancer cells and for MLK3-induced migration of mammary epithelial cells. Expression of active MLK3 is sufficient to induce the invasion of mammary epithelial cells, which requires AP-1 activity and is accompanied by the expression of several proteins corresponding to AP-1-regulated invasion genes. To assess MLK3's contribution to the breast cancer malignant phenotype in a more physiological setting, we implemented a strategy to inducibly express active MLK3 in the preformed acini of MCF10A cells grown in 3D Matrigel. Induction of MLK3 expression dramatically increases acinar size and modestly perturbs apicobasal polarity. Remarkably, MLK3 expression induces luminal repopulation and suppresses the expression of the pro-apoptotic protein BimEL, as has been observed in Her2/Neu-expressing acini. Taken together, our data show that MLK3-JNK-AP-1 signaling is critical for breast cancer cell migration and invasion. Our current study uncovers both a proliferative and novel antiapoptotic role for MLK3 in the acquisition of a malignant phenotype in mammary epithelial cells. Thus, MLK3 may be an important therapeutic target for the treatment of invasive breast cancer.
Introduction
Invasive ductal carcinoma accounts for 70% of invasive breast cancer. Cancer cell migration is fundamentally required for breast tumor invasion and metastasis. The migratory phenotype afforded to breast cancer cells is thought to be accompanied by a transient epithelialto-mesenchymal transition in which genes associated with migration and invasion are upregulated. Malignant breast cancer cells must also bypass normal growth arrest, evade apoptosis and gain limitless replicative potential (Hanahan and Weinberg, 2000) . These alterations are not always cancer-cell-autonomous. Interactions of breast cancer cells with extracellular matrix components and other cell types clearly influence phenotypic outcome.
Aberrant signal transduction pathways within tumor cells govern the malignant processes. Delineating the signaling pathways that contribute to the acquisition of the malignant phenotype in breast cancer is crucial for developing interventional strategies. Of the numerous proteins that have been implicated in breast cancer, kinases have emerged as excellent therapeutic targets (Zhang et al., 2009) , as evidenced by the use of the monoclonal antibody, Trastuzumab, and the smallmolecule, ATP mimetic, HER-2/epidermal growth factor receptor (EGFR) dual receptor tyrosine kinase inhibitor, lapatinib, in treating many patients with HER-2-positive breast cancer (Nielsen et al., 2009) .
The mitogen-activated protein kinase (MAPK) pathways respond to diverse extracellular stimuli to regulate cellular processes including proliferation, differentiation, migration, survival and apoptosis (Johnson and Lapadat, 2002) . The three best-characterized mammalian MAPKs are extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK) and p38. MAPKs have numerous cellular substrates, including transcription factors. For instance, JNK activates the heterodimeric transcription factor, AP-1, by phosphorylation of one of its components, c-jun. While the number of MAPK isoforms is rather limited, there are many more mitogen-activated protein kinase kinase kinases (MAP3Ks), suggesting that MAP3Ks may function as key nodes for integrating diverse extracellular stimuli with MAPK signaling. MLK3 is a widely expressed MAP3K that contributes to the activation of multiple MAPK pathways. MLK3 activates JNK and, in some experimental settings, also the p38 pathway, by phosphorylating the activation segment of the cognate MAP2K (Gallo and Johnson, 2002) . MLK3 apparently acts as a scaffold for the MAP3K, B-Raf, that is required for B-Raf-mediated ERK activation (Chadee and Kyriakis, 2004) . MLK3, with a predicted molecular weight of 92 kDa, contains an N-terminal src-homology-3 domain, followed by a kinase catalytic domain with similarity to both serine/threonine and tyrosine kinases, leucine zipper regions, a Cdc42/Rac-interactive binding motif and a large C-terminal tail rich in Ser, Thr and Pro residues (Gallo et al., 1994; Gallo and Johnson, 2002) . We previously discovered that MLK3 is autoinhibited through its src-homology-3 domain (Zhang and Gallo, 2001) . Activated Cdc42/Rac increases MLK3 catalytic activity (Teramoto et al., 1996) through binding to the Cdc42/Rac-interactive binding motif (Bock et al., 2000) and promoting activation loop (auto)phosphorylation (Du et al., 2005) . On the basis of work from our laboratory and by others (Leung and Lassam, 1998; Vacratsis and Gallo, 2000; Nihalani et al., 2001) , we propose that binding of the small GTPase, Cdc42 or Rac, disrupts src-homology-3-mediated autoinhibition, promoting leucine zipper-mediated dimerization and subsequent transphosphorylation within the catalytic domain to yield active MLK3.
Given its potential for diverse signaling, we undertook an investigation of the role of MLK3 in human breast cancer. Using gene silencing, as well as an MLK inhibitor, we show a crucial requirement for MLK3 in the migration of invasive breast cancer cells. In complementary experiments, induced expression of active MLK3 is shown to promote the migration of poorly invasive breast cancer and nontumorigenic mammary epithelial cells. Our data indicate that MLK3 signaling to JNK is crucial for breast cancer cell migration. In addition, MLK3 induces the expression of c-jun, fos-related antigen-1 (Fra-1) and vimentin, all of which have been associated with epithelial-to-mesenchymal transition and invasive breast cancer. We further show that MLK3 promotes invasion in an AP-1-dependent manner. To mimic how aberrant MLK3 signaling might affect the normal mammary ductal epithelium, active MLK3 was induced in preformed MCF10A mammary acini grown in a three-dimensional (3D) Matrigel culture system. MLK3 induction causes the mammary acini to bypass growth arrest, increase in size and reinitiate luminal filling. Thus, in the physiological context of a 3D Matrigel culture, MLK3 promotes the acquisition of the principal aspects of the malignant phenotype in mammary acini that, in some respects, mimic the pathological findings in ductal carcinoma in situ (DCIS) and invasive breast cancer.
Results

MLK3 is required for migration of highly invasive breast cancer cells
Total cellular lysates were generated from a panel of human mammary epithelial and breast cancer cell lines, and analyzed by western blotting using an MLK3-specific antibody. As shown in Figure 1 , higher levels of MLK3 protein were observed in the breast cancer cell lines MCF-7, T47D, SK-BR-3 and MDA-MB-231, as compared with that in the non-tumorigenic mammary epithelial cell lines 184B5 and MCF10A. No apparent correlation was found between MLK3 protein levels and steroid hormone receptor status or metastatic potential.
To probe the function(s) of MLK3 in breast cancer, a gene-silencing approach was taken. An Mlk3 short-hairpin Western blots of actin are shown as loading controls. MDA-MB-231 control cells or cells depleted of MLK3 were subjected to a transwell migration assay as described under Materials and methods. The cells were allowed to migrate toward 5% serum for 6 h. Triplicate wells were used for each of three independent experiments. The results are expressed relative to the migration of the control pSuper cells ( ¼ 100%). Migration was significantly inhibited in MDA-MB-231 cells stably expressing shMlk3 as compared with that in control pSuper-expressing cells. Column: Mean of three experiments; bar: s.e. P-value was determined by Student's t-test (*Po0.01). 
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J Chen et al RNA (shRNA) based on a previously validated short interfering RNA (siRNA) (Chadee and Kyriakis, 2004) was constructed in the pSuper vector and introduced into MDA-MB-231 cells using a retrovirus (Ory et al., 1996) . Stable populations of MDA-MB-231 cells containing pSuper-Mlk3 shRNA or the control vector pSuper were selected and subjected to proliferation and transwell migration assays. MLK3 knockdown was highly efficient as judged by western blotting (Figure 2a ). MLK3 knockdown had no effect on the proliferation of MDA-MB-231 cells in a twodimensional culture on plastic (Supplementary Figure 1a) . However, depletion of MLK3 dramatically reduced the migration of MDA-MB-231 cells by over four-fold in a 6-h transwell assay (Figure 2a) . Comparable results were observed upon transient silencing of MLK3 (data not shown). As an alternative approach to study migration, a wound-healing assay was used. As shown in Figure 2b , MDA-MB-231 cells depleted of MLK3 are significantly impaired in wound recovery measured at 16 h. By 24 h, control MDA-MB-231 cells had completely closed the wound, whereas an obvious wound remained in MLK3-depleted MDA-MB-231 cells. Due to the length of this assay, mitomycin-C was added to rule out any possibility of cell proliferation contributing to the observed phenotype.
To determine whether MLK3 has a more general role in the migration of other highly invasive breast cancer cell lines, a stable Mlk3-silenced population of MDA-MB-435 cells (Chambers, 2009) , generated as described above, and Hs578T cells transiently transfected with an Mlk3 siRNA were subjected to transwell migration assays. In agreement with our findings in MDA-MB-231 cells, Mlk3 silencing decreased the migration of the MDA-MB-435 and Hs578T cells by two-fold (Figures 2c and d) .
To assess whether the catalytic activity of MLK3 is required for breast cancer cell migration, a small ATP analog that selectively inhibits MLKs, CEP-11004 (Murakata et al., 2002; Shacka et al., 2006) , was added Figure 2b . Immediately after wounding, the medium was replaced with fresh growth medium and the vehicle or the indicated inhibitor (400 nM CEP-11004, 15 mM SP600125, 10 mM U0126 or10 mM SB203580). Representative photographs from three independent experiments, each performed in triplicate wells, at t ¼ 0 and at t ¼ 24 h are shown. Magnification: Â 10. MAPK, mitogen-activated protein kinase; MLK3, mixedlineage kinase-3; siRNA, short interfering RNA.
J Chen et al to MDA-MB-231 cells in a transwell migration assay. As shown in Figure 3a , CEP-11004 inhibits the migration of the MDA-MB-231 cells by two-fold, supporting the notion that breast cancer cell migration depends on MLK activity. Consistent with the previously described catalytic roles of MLK3 in JNK and p38 signaling, CEP-11004 blocked the activation of JNK and p38, but not ERK, as judged by western blotting using phosphospecific antibodies ( Figure 3b ). CEP-11004 also dramatically inhibited closure in a wound-healing assay of MDA-MB-231 cells ( Figure 3c ). A JNK inhibitor, SP600125, decreased wound closure. As has been previously reported, the p38 inhibitor, SB203580, decreased the migration of MDA-MB-231 cells (Timoshenko et al., 2007) . These data suggest that both p38 and JNK contribute to the migration of MDA-MB-231 cells, which may explain why the MLK inhibitor, which decreases both p38 and JNK activity, is more efficacious than either the JNK or p38 inhibitor in blocking the migration of these cells.
Induced expression of MLK3 promotes the migration of the poorly invasive MCF-7 breast cancer cells and of MCF10A mammary epithelial cells
In complementary experiments, we asked whether induced expression of active MLK3 could promote the migration of poorly invasive MCF-7 breast cancer cells (Zhang et al., 2004; Schachter et al., 2006) and MCF10A mammary epithelial cells. When a stable population of MCF-7-MLK3 cells was treated with the transcriptional inducer AP21967 and subjected to a transwell migration assay, a 2.5-fold increase in the migration of the MCF-7 cells ( Figure 4a ) was observed. Stable populations of MCF10A that inducibly express MLK3 were also generated and showed a two-fold increase in transwell migration upon transcriptional induction of MLK3 ( Figure 5a ). Induction of MLK3 potently induces JNK activation but has no effect on ERK activation in either MCF-7 or MCF10A cells. Induced expression of MLK3 results in a two-fold increase in p38 activity in both MCF-7 and MCF10A cells (Figures 4b and 5b ). In addition, MLK3 induction had no effect on ERK-5 activation in MCF10A cells (Supplementary Figure 2) . To assess the contributions of the MAPK pathways to MLK3-induced MCF-7 and MCF10A cell migration, transwell migration assays were performed in the presence of MAPK pathway inhibitors. The JNK inhibitor SP600125 was effective in blocking the MLK3-induced migration of both MCF-7 and MCF10A cells (Figures 4c and 5c ). The ERK pathway inhibitor also inhibited migration to a large extent, consistent with previous reports using these cell lines (Lester et al., 2005; Wilsbacher et al., 2006) . Our findings in MCF-7 and MCF10A cells that U0126 blocks MLK3-induced migration, even though MLK3 does not enhance ERK activation, is consistent with the idea that basal ERK activity is required for migration of these cells. Notably, basal ERK activation is observed in the absence of MLK3 induction in both MCF-7 and MCF10A cells. The p38 inhibitor did not inhibit MLK3-induced migration in these cell lines, suggesting that MLK3-induced p38 activity is not sufficient to drive the MLK3-induced migration of MCF-7 or MCF10A cells.
Western blotting of cellular lysates, using phosphospecific antibodies against active JNK, ERK and p38, as well as MAPKAPK2, a downstream effector of p38 (Young et al., 1997) , confirms that each inhibitor appropriately blocked its cognate pathway (Supplementary Figure 3) . The increased levels of active JNK and active ERK observed (Supplementary Figure 3) , upon treatment with the p38 inhibitor, likely reflect the previously reported antagonistic crosstalk between the p38 pathway and other MAPKs (Hall and Davis, 2002; Schachter et al., 2006) , as this phenomenon was also observed in MDA-MB-231 cells (Supplementary Figure 4) . (-) or with 25 nM AP21967 and subjected to a transwell migration assay as described under Materials and methods. The cells were allowed to migrate toward 10% FBS for 24 h. Triplicate wells were used for each of three independent experiments. The results are expressed relative to the migration of uninduced MCF-7-MLK3 cells ( ¼ 100%). Column: Mean of three experiments. Bar: s.e. P-value was determined by Student's t-test (*Po0.01). (b) MCF-7-MLK3 cells were treated with a vehicle (À) or 25 nM AP21967 for 20 h. Total cellular lysates containing 60 mg of total protein were analyzed by western blotting using the indicated antibodies. (c) MCF-7-MLK3 cells were seeded in a Boyden chamber in a medium containing the vehicle (À) or 25 nM AP21967, and the indicated inhibitors (SP ¼ 15 mM SP600125, U0 ¼ 10 mM U0126 or SB ¼ 10 mM SB203580), and subjected to a transwell migration assay as described under Materials and methods. The cells were allowed to migrate toward 10% FBS for 24 h. Triplicate wells were used for each of two independent experiments. The results are expressed relative to the migration of uninduced MCF-7-MLK3 cells ( ¼ 100%). Column: Mean of two independent experiments. Bar: s.e. FBS, fetal bovine serum; MLK3, mixed-lineage kinase-3.
Collectively, these data indicate that MLK3 expression is sufficient to activate JNK signaling, which is crucial for the MLK3-mediated migration of MCF-7 and MCF10A cells.
Induced expression of MLK3 increases mammary acinar size in an MLK3-JNK-dependent pathway Three-dimensional cell culture systems provide a physiologically appropriate environment for assessing the effect of oncogenes on mammary epithelium (Debnath and Brugge, 2005; Lee et al., 2007) . To determine whether MLK3 disrupts normal mammary morphogenesis, the inducible MLK3 expression system was used to express active MLK3 in preformed acinar structures composed of growth-arrested, polarized MCF10A cells. A population of stable, inducible MCF10A-MLK3 cells was seeded in Matrigel cultures under low epidermal growth factor (EGF) (0.1 ng/ml) and standard EGF (5 ng/ml) concentrations. Polarized, hollow acini were established by day 10 as judged by confocal sectioning of acini after 4 0 ,6-diamidino-2-phenylindole and GM130 staining (data not shown). After 10 days, cultures were treated with AP21967 to induce the expression of MLK3. As is readily apparent at day 20 (Figure 6a ), compared with uninduced MCF10A-MLK3 acini, induced expression of MLK3 dramatically increases acinar size under both EGF concentrations. Induction of MLK3 expression resulted in a 2.8-and a 2.0-fold increase in acinar cross-sectional area under low and standard EGF concentrations, respectively (Figure 6b ). Data from a morphometric analysis of acinar cross-sectional area performed at day 20 are presented in a box-and-whiskers plot (Figure 6c ). Using the corresponding control vector-expressing MCF10A cells, endogenous MLK3 levels (Supplementary Figure  5a) and acinar structures (Supplementary Figure 5b) were unaffected by AP21967. Highlighting the importance of the 3D environment for the MLK3-mediated effects on growth and morphogenesis, induced expression of MLK3 in MCF10A-MLK3 cells cultured on two-dimensional plastic does not induce proliferation (Supplementary Figure 1b) .
Addition of CEP-11004 at the time of MLK3 induction prevents the increased size of MCF10A-MLK3 acini, indicating a requirement for MLK3 activity (Figure 6d ). The JNK inhibitor also prevented the MLK3-induced phenotype. The inhibitors had no observable effects on uninduced mammary acini. These data indicate that active MLK3 signaling to JNK is required for the effects of induced MLK3 in 3D culture.
Induced MLK3 bypasses growth arrest, initiates luminal repopulation of preformed mammary acini and suppresses Bim expression By day 20 in Matrigel culture, the acini derived from MCF10A cells should be growth-arrested (Debnath and Brugge, 2005) . To determine whether induction of active MLK3 is sufficient to bypass growth arrest, acini were examined for expression of the proliferating-cell antigen, Ki-67, at day 20. As shown in Figure 7a , fewer than 10% of uninduced MCF10A-MLK3 acini contained Ki-67-positive cells in cultures containing both low and standard EGF concentrations, whereas greater than 70 and 90% of MLK3-induced acini contained at least one Ki-67-positive cell in cultures with low and standard EGF concentrations, respectively. It should be noted that although the majority of the MLK3-induced acini contained multiple proliferating cells, Ki-67-positive cells were still in the minority. AP21967 does not affect Figure 5 Induced expression of MLK3 promotes the migration of MCF10A cells. (a) MCF10A-MLK3 cells were seeded in a Boyden chamber with the vehicle or with 25 nM AP21967 and subjected to a transwell migration assay as described under Materials and methods. The cells were allowed to migrate toward 2% horse serum for 24 h. Triplicate wells were used for each of three independent experiments. The results are expressed relative to the migration of uninduced MCF10A-MLK3 cells ( ¼ 100%) (lower panel). Column: Mean of three experiments. Bar: s.e. P-value was determined by Student's t-test (*Po0.05). (b) MCF10A-MLK3 cells were treated with a vehicle (À) or with 25 nM AP21967 in media containing 2% horse serum and 20 ng/ml EGF for 20 h. Cellular lysates containing 60 mg of total protein were analyzed by western blotting using the indicated antibodies. (c) MCF10A-MLK3 cells were seeded in a Boyden chamber in a medium containing the vehicle (À) or 25 nM AP21967, and the indicated inhibitors (SP ¼ 15 mM SP600125, U0 ¼ 10 mM U0126, SB ¼ 10 mM SB203580 or CEP ¼ 400 nM CEP-11004), and subjected to a transwell migration assay as described under Materials and methods. The cells were allowed to migrate toward 2% horse serum for 24 h. Triplicate wells were used for each of two independent experiments. The results are expressed relative to the migration of uninduced MCF10A-MLK3 cells ( ¼ 100%). Column: Mean of two independent experiments. Bar: s.e. EGF, epidermal growth factor; MLK3, mixed-lineage kinase-3.
J Chen et al Figure 5c) . The ability of induced MLK3 to substantially increase mammary acinar size and proliferation under minimal EGF concentrations suggests that MLK3 signaling partially overrides the growth factor dependence of the mammary acini. To determine whether increased acinar size caused by MLK3 affects polarity and luminal filling, structures were stained with nuclear and polarity markers, and optical sections through acini were examined. As shown in Figure 7b (left panel), at day 20, in the absence of AP21967, the MCF10A-MLK3 cells form uniform spherical structures with hollow lumens, whereas after culturing in the presence of AP21967 from day 10 to day 20, the lumens are largely filled, indicating that MLK3 can initiate luminal repopulation (Figure 7b , center and right panels). Similar luminal filling was observed upon MLK3 induction in cultures containing 0.1 ng/ml EGF (data not shown). Whereas induction of the oncogene ErbB2 promotes the formation of multi-acinar structures (Muthuswamy et al., 2001) , the majority of the MLK3-expressing acini are still spherical (Figure 7b , central panel), with cell polarity largely maintained as determined by staining with the apical Golgi marker, GM130. However, some poorly defined mass-like structures with apparent disruption of cell polarity are also observed (Figure 7b, right panel) . Taken together, these results show that expression of active MLK3 in mature acini reinitiates proliferation in growth-arrested structures, repopulates the lumen and can perturb cell polarity.
Ki-67 positivity in vector control cells (Supplementary
BimEL is a BH3-only proapoptotic protein that has been shown to be crucial in luminal apoptosis and lumen formation (Reginato et al., 2005) . Oncogenes, like v-Src and ErbB2, which promote luminal filling of mammary acini, have been shown to suppress the expression of Figure 6 Induced expression of MLK3 increases the size of pre-established mammary acini. MCF10A-MLK3 cells were seeded in an overlay medium containing 0.1 or 5 ng/ml EGF on Matrigel as described under Materials and methods. (a) Fresh medium containing vehicle or 50 nM AP21967 was added to cultures on day 10 and images were acquired on day 20 of culture. Scale bar: 50 mm. (b) The cross-sectional area of MLK3-induced acini relative to that of uninduced acini ( ¼ 100%). Each column represents at least 300 acini per condition combined from three independent experiments. The error bar indicates the s.d. (c) Cross-sectional pixel areas of individual acini were determined as described under Materials and methods, and plotted as a box plot. Black line, median value; spread, interquartile range; circles, outliers. The data are from a representative set of three independent experiments where B150 acini per condition were measured. (d) MCF10A-MLK3 cells were seeded in an overlay medium containing 0.1 ng/ml EGF on Matrigel as described under Materials and methods. Fresh medium containing a vehicle (À) or 50 nM AP21967, and the indicated inhibitor (400 nM CEP-11004 or 15 mM SP600125), was added on day 10 and images were acquired on day 18. Scale bar: 50 mm. Representative photographs from one of three independent experiments, each performed in duplicate wells. EGF, epidermal growth factor; MLK3, mixed-lineage kinase-3.
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BimEL (Reginato et al., 2005) . Consistent with these findings, upon MLK3 induction, we observe a dramatic decrease in BimEL levels on the basis of western blotting of lysates derived from 3D cultures of MCF10A-MLK3 cells (Figure 7c ). These data show that, in the physiologically appropriate 3D context of mammary acini, MLK3 has both proliferative and antiapoptotic activities.
MLK3 induces the expression of proteins associated with invasive breast cancer
Our data indicate a central role for JNK in the MLK3-mediated malignant phenotypes. MLK3 can act as an MAP3K to activate JNK, which, in turn, can phosphorylate and activate c-jun, a component of the AP-1 transcription factor (Gallo and Johnson, 2002) . We hypothesized that MLK3 signaling to JNK might activate c-jun to drive the expression of AP-1-regulated invasion genes in MCF10A cells. Notable AP-1-regulated invasion genes include c-jun (Karin, 1995; Minet et al., 2001; Zajchowski et al., 2001) , Fra-1 (Bergers et al., 1995; Zajchowski et al., 2001 ) and vimentin (Rittling et al., 1989; Sommers et al., 1994b; Zajchowski et al., 2001; Rizki et al., 2007) Induced expression of MLK3 in MCF10A cells increases the level of c-jun (Figure 8a ), Fra-1 (Figure 8b ) and vimentin (Figure 8b ), 0 ,6-diamidino-2-phenylindole (blue), and analyzed by confocal microscopy. Optical sections through the largest cross-sectional area of representative acini are shown. The white arrows indicate loss of polarity. Scale bar: 20 mm. (c) MCF10A-MLK3 cells were seeded in an overlay medium containing 5 ng/ml EGF on Matrigel as described under Materials and methods. Fresh medium containing a vehicle or 50 nM AP21967 was added to the cultures on day 7. On the indicated days in culture, cellular lysates were prepared as described under Materials and methods, and subjected to western blot analysis using the indicated antibodies. Actin was used as a loading control. The data are representative of two independent experiments. EGF, epidermal growth factor; MLK3, mixed-lineage kinase-3.
supporting the notion that MLK3 promotes a malignant phenotype, at least in part, by controlling AP-1 activity. Notably, vimentin expression is also induced upon induction of MLK3 in preformed MCF10A mammary acini (Figure 8c ).
MLK3 promotes invasion through signaling to AP-1
To investigate whether MLK3 regulates AP-1 activity to promote a malignant phenotype, the effect of MLK3 on the invasion of MCF10A cells was first examined. Induced expression of MLK3 in MCF10A-MLK3 cells increased invasion through Matrigel by three-fold in transwell invasion assays (Figure 9a) . To test the requirement of AP-1 in MLK3-induced invasion, we made use of the dominant-negative mutant, Tam67 (Brown et al., 1993) , which lacks the N-terminal transactivating domain, as an inhibitor of AP-1 activity. Expression of pBabe-Tam67 (Johung et al., 2007) , but not the pBabe control vector, effectively blocks MLK3-induced invasion (Figure 9a ), indicating that MLK3 regulation of AP-1 activity is crucial for the invasive phenotype. As shown in Figure 9b , Tam67 is efficiently expressed in MCF10A-MLK3 cells and prevents the MLK3 induction of the AP-1-regulated invasion gene, Fra-1. In a complementary experiment, silencing of c-jun, an AP-1 component and a direct substrate of JNK, also blocks the MLK3-induced expression of Fra-1 (Figure 9c ). These data, taken together, show that MLK3-JNK signaling increases AP-1 activity to promote the invasion of mammary epithelial cells.
Discussion
Identifying signaling pathways that contribute to breast cancer progression is principal to developing effective targeted therapies. MLK3 controls multiple MAPK signaling pathways and, depending on the cellular context, regulates proliferation, apoptosis, differentiation and migration. Several human breast cancer cell lines show higher levels of MLK3 compared with nontumorigenic mammary epithelial cell lines (Figure 1 ). Using the Oncomine database (www.oncomine.com) (Rhodes et al., 2007) , we found that MLK3 was among the top 10% overexpressed transcripts in DCIS as compared with normal breast tissue (Radvanyi et al., 2005 ), but it is also possible that MLK3 protein levels may be regulated at the translational and/or posttranslational levels.
Using Mlk3 silencing (Figure 2 ) as well as an MLKselective inhibitor (Figures 3 and 5) we provide evidence that MLK3 catalytic activity is crucial for migration of mammary cancer and epithelial cells. Studies with MAPK pathway inhibitors support the idea that MLK3-JNK signaling drives migration. Indeed, Slpr, the Mlk homolog in Drosophila, signals to JNK to promote epithelial sheet movement during the dorsal closure of the fly embryo (Stronach and Perrimon, 2002) , in a genetically mapped pathway that leads to induction of JNK and AP-1 (Jacinto et al., 2002) . Interestingly, using an MCF10A wound-healing assay, a large-scale RNA interference screen targeting over 1000 genes encoding all protein kinases and phosphatases, as well as a battery of proteins predicted to influence cell migration, identified over 60 genes as modulators of migration, one of which was Mlk3. (Simpson et al., 2008) . A scaffolding function for MLK3 has been proposed for migration of A549 lung carcinoma cells (Swenson-Fields et al., 2008) . However, our findings that an MLK inhibitor can block the migration of invasive breast cancer cells and that JNK inhibition blocks MLK3-induced migration in MCF-7 and MCF10A cells supports the idea that, at least in the context of breast cancer, MLK3-JNK signaling is crucial for cell migration. Indeed, a significant body of literature indicates a requirement for JNK in cancer progression (Cui et al., 2006; Ching et al., 2007; Dhillon et al., 2007; Khatlani et al., 2007; Vivanco et al., 2007; Su et al., 2009; Wagner and Nebreda, 2009) .
It is interesting to note that both MDA-MB-231 and MCF-7 cells contain similar levels of MLK3, yet MDA-MB-231 cells are more migratory than MCF-7 cells. As MDA-MB-231 cells are highly malignant, it is likely MCF10A-MLK3 cells were seeded in growth media and induced with 25 nM AP21967 for 20 h. Cellular lysates containing 25 mg of total protein were subjected to western blotting using the indicated antibodies. The data are representative of three independent experiments. (c) MCF10A-MLK3 cells were seeded in 0.1 ng/ml EGF as described under Materials and methods. Expression of MLK3 was induced with 50 nM AP21967 on day 10, and on day 20 cultures were immunostained with anti-vimentin (green) and stained with 4 0 ,6-diamidino-2-phenylindole (blue). The data are representative of three independent experiments. Scale bar: 50 mm. Fra-1, fos-related antigen-1; MLK3, mixed-lineage kinase-3.
MLK3 signaling in breast cancer J Chen et al that multiple facets of the migratory machinery and signaling are aberrantly activated, contributing to their highly invasive phenotype. In MCF-7 cells, these signaling pathways are likely less active and thus high, induced MLK3-JNK signaling is needed to increase migration.
In DCIS, partial-to-complete filling of the luminal space is commonly observed and a poorer prognosis is associated with disruption of apicobasal polarity (Debnath and Brugge, 2005) . 3D mammary epithelial cell cultures provide a structurally appropriate milieu for investigating breast cancer phenotypes. MCF10A cells grown in 3D Matrigel form growth-arrested, hollow spheroids composed of polarized cells that recapitulate many aspects of the normal mammary glandular architecture (Debnath and Brugge, 2005) . Upon expression of certain oncogenes such as cyclin-D1 and HPV E7 (Debnath et al., 2002; Shaw et al., 2004; Debnath and Brugge, 2005) , MCF10A acini grown in Matrigel increase in size but maintain apicobasal polarity and hollow lumens. A few oncogenes, such as ErbB2, Notch and the Ets family of transcription factors, are able to confer DCIS and invasive breast cancer traits on MCF10A cells, forming filled lumens and disorganized structures when grown in Matrigel cultures (Muthuswamy et al., 2001 , Shaw et al., 2004 . In this DCIS model, we induced the expression of active MLK3 in preformed, hollow MCF10A mammary acini and observed multiple features of DCIS, including bypass of growth arrest and re-initiation of luminal filling. The increase in the proliferative marker Ki-67 and suppression of the proapoptotic BimEL (Figure 7 ) upon MLK3 induction reveals both proliferative and novel antiapoptotic roles for MLK3 in the context of breast cancer.
The ability of MLK3 to regulate cell proliferation is highly dependent upon 3D culture in extracellular matrix. Growth of MDA-MB-231 cells in 3D Matrigel culture is largely stunted by silencing of MLK3 (data not shown), whereas proliferation on two-dimensional plastic is not enhanced by either induction of MLK3 in MCF10A cells or by silencing of Mlk3 in MDA-MB-231 cells (Supplementary Figure 1) . These data indicate the importance of physiologically relevant 3D culture systems in assessing oncogenic phenotypes.
One of the major outcomes of MLK3-JNK signaling is phosphorylation of c-jun and activation of AP-1. In mammary epithelial cells, MLK3 induces the expression of c-jun, Fra-1 and vimentin whose genes are regulated by AP-1 and have been shown to be expressed at higher levels in invasive human breast cancer cell lines, Figure 9 Induced expression of MLK3 promotes the invasion of MCF10A cells and MLK3-induced invasion requires AP-1 activity. (a) MCF10A-MLK3 cells carrying pBabe or pBabe-Tam67 retroviral vectors were seeded in a Matrigel-coated Boyden chamber with a vehicle or with 25 nM AP21967 and subjected to a transwell invasion assay as described under Materials and methods. The cells were allowed to migrate toward 2% horse serum for 24 h. Triplicate wells were used for each of two independent experiments. The results are expressed relative to the invasion of uninduced MCF10A-MLK3 cells ( ¼ 100%). Column: Mean of two experiments. Bar: s.e. (b) MCF10A-MLK3 cells carrying pBabe or pBabe-Tam67 retroviral vectors were induced with 25 nM AP21967 for 20 h. Cellular lysates containing 25 mg of total protein were subjected to western blotting using the indicated antibodies. The data are representative of three independent experiments. (c) MCF10A-MLK3 cells were treated with a control or with c-jun siRNA for 24 h followed by addition of 25 nM AP21967 for 20 h. Cellular lysates containing 25 mg of total protein were subjected to western blotting using the indicated antibodies. The data are representative of three independent experiments. MLK3, mixed-lineage kinase-3. compared with that in non-invasive breast cancer cell lines (Sommers et al., 1994a; Zajchowski et al., 2001) . Vimentin is a classical marker for epithelial-to-mesenchymal transition, a transient cellular differentiation that allows cancer cell migration and invasion (Blick et al., 2008; Polyak and Weinberg, 2009) . A subset of MLK3-expressing MCF10A acini also showed disruption of apicobasal polarity, a feature of invasive breast cancer. Furthermore, MLK3 promotes the invasion of MCF10A cells (Figure 9 ). Our finding that the dominant-negative AP-1 inhibitor, Tam 67, blocks MLK3-induced invasion indicates a crucial role for MLK3-JNK-AP-1 in invasion. Notably, decreased phospho-JNK1/2 levels are reported to correlate with improved overall survival in infiltrating ductal carcinoma (Yeh et al., 2006) . In summary, our investigation supports a crucial role for MLK3-JNK-AP-1 signaling in breast cancer cell migration and acquisition of a malignant phenotype. Although JNK has, in the past, been largely associated with stress signaling and neuronal apoptosis, a body of evidence linking JNK to cell migration, invasion and proliferation is accumulating. Our data are consistent with the idea that JNK signaling to AP-1 activates genes associated with epithelial-to-mesenchymal transition and a breast cancer invasive phenotype. Global gene expression analyses are underway to determine the repertoire of genes, including AP-1-regulated genes, affected by MLK3 in breast cancer. However, given the array of cellular substrates for JNK and other MLK3-regulated pathways, it will also be important to determine whether MLK3 signaling affects the cytoskeleton in the context of breast cancer. Finally, our finding that an MLK inhibitor is able to inhibit breast cancer cell migration and suppress the MLK3-induced phenotype of MCF10A cells in 3D culture indicates that MLK inhibitors may be useful in treating invasive breast cancer.
Materials and methods
Chemicals, antibodies, siRNAs and DNA constructs For a complete list see theSupplementary information. Oligonucleotides for shRNAs targeting human MLK3 (Chadee and Kyriakis, 2004) were designed using OligoEngine 2.0, annealed and subcloned into the pSuper-retro vector (OligoEngine Inc., Seattle, WA, USA). Construction of the inducible vector encoding Flag-tagged MLK3, pLH-Z 12 I-PL 2 -MLK3, was previously described (Zhang et al., 2004) .
Cell lines, cell culture, transfection and lysis See Supplementary information for further details. Human mammary epithelial and breast cancer cell lines were from ATCC (Manassas, VA, USA). MCF-7 cells engineered to inducibly express MLK3 (MCF-7-MLK3) were previously described (Zhang et al., 2004) . A population of MCF10A cells was engineered to inducibly express MLK3 (MCF10A-MLK3) or an empty vector control. Breast cancer cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco BRL, Paisley, PA, USA) with 10% fetal bovine serum (FBS). Transfection of siRNA (Mlk3-specific siRNA (10 nM), c-junspecific siRNA (100 nM) or a universal control siRNA) was performed using InterferIN (Polyplus-transfection, New York, NY, USA) according to the manufacturer's instructions. Cells were lysed as described previously (Bock et al., 2000) . The protein concentrations of the lysates were determined by the Bradford method (Bio-Rad, Hercules, CA, USA). For detection of MLK3 protein levels in human mammary epithelial cells and breast cancer cells, the cells were harvested and lysed in radioimmunoprecipitation assay buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS) containing protease inhibitors. The protein concentrations of the lysates were determined by the BCA protein assay (Pierce, Rockford, IL, USA). For detection of proteins in MCF10A cells grown in 3D culture, the cells were lysed by combining the Matrigel culture with an equal volume of radioimmunorecipitation assay lysis buffer containing protease inhibitors and passing through a 25-gauge needle; the lysates were clarified by centrifugation at 14 000 r.p.m. for 15 min before immunoblotting (Reginato et al., 2005) .
Gel electrophoresis and western blot analysis Cellular lysates were resolved by SDS-polyacrylamide gel electrophoresis. The proteins were transferred to nitrocellulose membranes and immunoblotted using appropriate antibodies followed by treatment with a horseradish peroxidaseconjugated or an IRDye-conjugated secondary antibody and developed by the chemiluminescence method or visualized by fluorescence (Li-COR Biosciences, Lincoln, NE, USA), respectively.
Transwell migration and invasion assays
Chemotactic migration or invasion was quantified using a Boyden chamber transwell assay (8 mm pore size; Corning Costar, Cambridge, MA, USA) using uncoated or Matrigelcoated filters, respectively. Cells were deprived of serum overnight, trypsinized and introduced into the upper chamber (5 Â 10 4 for MDA-MB-231, MDA-MB-435 and Hs578T (6 h); 10 5 for MCF-7-MLK3 and MCF10A-MLK3 (24 h)). For the 24-h assays, mitomycin-C was included. The chemoattractant in the lower chamber was medium supplemented with 5% FBS (MDA-MB-231, MDA-MB-435 and Hs578T), 10% FBS (MCF-7-MLK3) or 2% horse serum (MCF10A-MLK3). The cells were fixed and stained as described by Goicoechea et al. (2009) . Migrated cells in five randomly chosen fields were counted. The experiments were performed in triplicate wells and each experiment was performed at least two or three times as indicated.
Wounding-healing assay MDA-MB-231 cells and derivatives were grown to confluence. The growth medium was replaced with fresh medium supplemented with mitomycin-C (1 mg/ml) and the monolayer of cells was scratched using a 200 ml pipette tip. Wound width was monitored over time by microscopy. Percentage wound recovery was expressed as follows: [1-(Width of the wound at a given time/width of the wound at t ¼ 0)] Â 100%.
3D morphogenesis assay
See Supplementary information for details. A single-cell suspension of 5000 cells was seeded per well on solidified Matrigel (BD Biosciences, San Jose, CA, USA) in overlay media (Debnath et al., 2003; Lee et al., 2007) . After formation of mature acini, at day 10, MLK3 expression was induced with 50 nM AP21967 and cultures were assessed on day 20. All immunofluorescence procedures were performed as previously described (Debnath et al., 2003) . Acinar structures at day 20 were analyzed for size distribution using Metamorph.
